Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories (NY: BIO )

379.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 379.00
Bid (Size) 368.11 (1)
Ask (Size) 390.55 (1)
Prev. Close 379.00
Today's Range 379.00 - 379.00
52wk Range 344.63 - 572.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Death Cross Looms Over Bio-Rad Laboratories Investors
 
Via Benzinga
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga

Performance

YTD
-10.28%
-10.28%
1 Month
-16.50%
-16.50%
3 Month
-21.53%
-21.53%
6 Month
-4.87%
-4.87%
1 Year
-29.53%
-29.53%

More News

Read More
Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Stocks Roar Back To Life; Still Pacing For Weekly Loss
Via Talk Markets
Recap: Bio-Rad Laboratories Q1 Earnings
Via Benzinga
Golden Cross Appears Before Bio-Rad Laboratories Investors
Via Benzinga
Earnings Scheduled For February 16, 2023
Via Benzinga
Earnings Outlook For Bio-Rad Laboratories
Via Benzinga
Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Bio-Rad Reports First-Quarter 2023 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
From Bio-Rad Laboratories, Inc.
Via Business Wire
The 3 Most Promising Biotech Stocks to Buy Now
Via InvestorPlace
I Asked ChatGPT for 10 EV Stocks to Buy. Here’s What It Recommended.
Via InvestorPlace
Bio-Rad to Participate in Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
From Cytek Biosciences, Inc.
Via GlobeNewswire
Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover
Via Investor's Business Daily
Thoughts For Thursday: All Eyes On The CPI
Via Talk Markets
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says
Via Benzinga
Bio-Rad To Participate in Fireside Chat During Credit Suisse’s 31st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Third-Quarter 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
From Bio-Rad Laboratories, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.